Compare ODC & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | IMTX |
|---|---|---|
| Founded | 1941 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 1994 | N/A |
| Metric | ODC | IMTX |
|---|---|---|
| Price | $102.33 | $9.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 108.1K | ★ 345.9K |
| Earning Date | 06-04-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $61.30 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $45.61 | $5.05 |
| 52 Week High | $107.00 | $12.41 |
| Indicator | ODC | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.57 | 42.81 |
| Support Level | $98.50 | $8.98 |
| Resistance Level | $106.84 | $10.67 |
| Average True Range (ATR) | 3.67 | 0.54 |
| MACD | -0.49 | -0.02 |
| Stochastic Oscillator | 39.34 | 17.91 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.